The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 4, Pages 3226
Publisher
MDPI AG
Online
2023-02-07
DOI
10.3390/ijms24043226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
- (2022) Siting Yu et al. Frontiers in Oncology
- Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis
- (2022) Alexandra Giatromanolaki et al. BREAST CANCER RESEARCH AND TREATMENT
- Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
- (2022) Song-Yang Wu et al. Molecular Cancer
- Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
- (2022) Yang Fu et al. Frontiers in Endocrinology
- Measurement of Perfusion Heterogeneity within Tumor Habitats on Magnetic Resonance Imaging and Its Association with Prognosis in Breast Cancer Patients
- (2022) Hwan-ho Cho et al. Cancers
- Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma
- (2022) Domenico Ribatti et al. Frontiers in Oncology
- Immunotherapy and breast cancer: an overview
- (2022) Essia Mezni et al. CURRENT OPINION IN ONCOLOGY
- Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
- (2022) Sukhraj Pal Singh Dhami et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
- (2022) Javier Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer
- (2022) Nabeel Kajihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunosuppressive effects of vascular endothelial growth factor (Review)
- (2022) Domenico Ribatti Oncology Letters
- Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients
- (2021) Kirti Kajal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment
- (2021) Valeria Lucarini et al. Cancers
- Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
- (2021) Ashraf Ul Kabir et al. Science Translational Medicine
- Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications
- (2021) Ying Zhang et al. Frontiers in Oncology
- Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
- (2021) Zowi R. Huinen et al. Nature Reviews Clinical Oncology
- Angiogenesis as a hallmark of solid tumors - clinical perspectives
- (2021) Jamal Majidpoor et al. CELLULAR ONCOLOGY
- Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
- (2021) Anita K. Mehta et al. Frontiers in Immunology
- Angiogenesis induction in breast cancer: A paracrine paradigm
- (2021) Nilaja Badodekar et al. CELL BIOCHEMISTRY AND FUNCTION
- DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression
- (2021) Naidong Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
- (2021) Wuzhen Chen et al. Biomarker Research
- The emerging role of immune checkpoint inhibitors for the treatment of breast cancer
- (2021) Frederick M. Howard et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mouse Breast Carcinoma Monocytic/Macrophagic Myeloid-Derived Suppressor Cell Infiltration as a Consequence of Endothelial Dysfunction in Shb-Deficient Endothelial Cells Increases Tumor Lung Metastasis
- (2021) Qi He et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
- (2021) Dora Hammerl et al. Nature Communications
- Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
- (2020) Caroline Bergenfelz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
- (2020) Giovanna Garufi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
- (2020) Claudia Ceci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- BMP9 signaling promotes the normalization of tumor blood vessels
- (2020) Claire Viallard et al. ONCOGENE
- An Overview of Vasculogenic Mimicry in Breast Cancer
- (2020) Marco A. Andonegui-Elguera et al. Frontiers in Oncology
- Vasculogenic mimicry in carcinogenesis and clinical applications
- (2020) Qingxi Luo et al. Journal of Hematology & Oncology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- VEGF165b and its mutant demonstrate immunomodulatory, not merely anti-angiogenic functions, in tumor-bearing mice
- (2020) Huiyong Zhang et al. MOLECULAR IMMUNOLOGY
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
- (2020) Ombretta Melaiu et al. SEMINARS IN CANCER BIOLOGY
- Cancer statistics for adolescents and young adults, 2020
- (2020) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- (2020) Won Suk Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer
- (2020) Masanori Oshi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer
- (2020) Ellen C. de Heer et al. JOURNAL OF CLINICAL INVESTIGATION
- M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2
- (2020) Fang Dong et al. Cell Death & Disease
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Vascular regulation of antitumor immunity
- (2019) Lance L. Munn et al. SCIENCE
- T Regulatory Cells and Priming the Suppressive Tumor Microenvironment
- (2019) Christina M. Paluskievicz et al. Frontiers in Immunology
- Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade
- (2019) Qian Li et al. CLINICAL CANCER RESEARCH
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
- (2018) Xichen Zheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
- (2018) Rindert Missiaen et al. SEMINARS IN CANCER BIOLOGY
- 72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
- (2018) M Quintela-Fandino et al. ANNALS OF ONCOLOGY
- Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
- (2018) Florence T. H. Wu et al. BRITISH JOURNAL OF CANCER
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Vascular heterogeneity and specialization in development and disease
- (2017) Michael Potente et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma
- (2017) Lei Qin et al. NEURORADIOLOGY
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade
- (2017) Chiara Secondini et al. OncoImmunology
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
- (2016) Florence T.H. Wu et al. CANCER RESEARCH
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- Tumour angiogenesis-Origin of blood vessels
- (2016) S. Krishna Priya et al. INTERNATIONAL JOURNAL OF CANCER
- Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
- (2016) Domenico Ribatti et al. Translational Oncology
- Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects
- (2016) Xiao-hua Jia et al. Oncotarget
- Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification
- (2015) Xiao-li Dai et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Angiopoietin-2 is a negative prognostic marker in small cell lung cancer
- (2015) Israel Cañadas et al. LUNG CANCER
- Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
- (2015) Rafael Carretero et al. NATURE IMMUNOLOGY
- Role of endothelial progenitor cells in cancer progression
- (2014) Michele Moschetta et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells
- (2014) HAIYAN WANG et al. Experimental and Therapeutic Medicine
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
- (2013) D. Gerald et al. CANCER RESEARCH
- Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
- (2013) Erika Hamilton et al. Clinical Breast Cancer
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- A Proangiogenic Signature Is Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell Carcinoma
- (2013) R. Gyanchandani et al. MOLECULAR CANCER RESEARCH
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
- (2012) Adam Brufsky et al. BREAST CANCER RESEARCH AND TREATMENT
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
- (2012) Christoph Thomssen et al. ONCOLOGY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
- (2012) Jaclyn Sceneay et al. OncoImmunology
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
- (2011) Yingzi Ge et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
- (2011) J.-L. Li et al. CANCER RESEARCH
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Molecular control of endothelial cell behaviour during blood vessel morphogenesis
- (2011) Shane P. Herbert et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)
- (2011) Larry D. Sasich et al. SAUDI PHARMACEUTICAL JOURNAL
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Vascular endothelial growth factor receptor-2 in breast cancer
- (2010) Shanchun Guo et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma
- (2010) Mahboobeh Razmkhah et al. CELLULAR IMMUNOLOGY
- Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
- (2010) Gang Niu et al. CURRENT DRUG TARGETS
- Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth
- (2009) Patrick Nasarre et al. CANCER RESEARCH
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
- (2009) C. L. Roland et al. MOLECULAR CANCER THERAPEUTICS
- Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging
- (2009) Benjamin J Vakoc et al. NATURE MEDICINE
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance
- (2008) Paola Allavena et al. IMMUNOLOGICAL REVIEWS
- CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NFκB through the CBM (Carma3/Bcl10/Malt1) Complex
- (2008) Daniel Martin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started